Hey there! Welcome!
Get updated on
Top Picks

calendar
1 Mar, 24
dot
link
Source

calendar
26 Mar, 24
This Indian study demonstrated telmisartan to be efficacious and tolerable for BP control in Indian hypertension patients when used as monotherapy or in combination therapy. The benefits of telmisartan were independent of age, duration, and stages of hypertension.

calendar
16 Apr, 24
dot
link
BMC Oral Health.
In a recent investigation among adults in the United States, researchers observed a positive correlation between mean platelet volume (MPV) & periodontal disease. Individuals with moderate to severe periodontitis exhibited higher MPV levels (OR = 1.090). Specifically, those in the upper tertile of MPV demonstrated a 21.6% increased likelihood of developing periodontitis vs. those in the lowest tertile (OR = 1.216).

calendar
16 Apr, 24
dot
link
JAMA Netw Open.
Over a 17-year study period, researchers observed that women with untreated or newly diagnosed hypertension faced an elevated risk of developing fibroids (Hazard ratios, 1.19 & 1.45 respectively). Conversely, those receiving antihypertensive treatment showed a reduced risk (HR, 0.63), suggesting that managing blood pressure could potentially serve as a preventive measure against fibroids.
Pulse IconPulse CheckCounter Icon0

How frequently do you encounter a history of hypertension in women who present with fibroids?


calendar
17 Apr, 24
dot
link
Br. J. Dermatol.
  • Treatment of scabies with benzyl benzoate 25% demonstrated an excellent cure rate compared to topical permethrin (87% vs 27%)
  • Topical benzyl benzoate exhibited reasonable tolerability; 43% of patients exhibited burning sensation
  • Findings indicated, topical benzyl benzoate as an appropriate first-line therapy in the treatment of scabies

calendar
17 Apr, 24
dot
link
J Clin Gastroenterol...
  • A meta-analysis showed that rifaximin (>1200 mg/day) significantly improved bloating symptoms vs. placebo (44.6% vs 34.6%, RR 1.22) in functional gastrointestinal disorder patients; however, doses <1200 mg/day were comparable to placebo (P=0.09)
  • Rifaximin led to a greater reduction in bloating scores compared with placebo (standardized mean difference −0.3, P=0.04) but results showed heterogeneity

home
home
home